Attend PACK EXPO – this year’s can’t-miss event in Chicago, Oct 23-26.
Discover solutions from 2,000+ exhibitors to advance your operations and network with colleagues at PACK EXPO International.
REGISTER TODAY

Schott Establishes Standalone Company for Pharma Business

The separate legal entity will create more room for organic and inorganic growth and further potential investments toward becoming climate neutral by 2030.

An employee is checking pharma containment solutions. Schott Pharma produces around 13 billion products per year.
An employee is checking pharma containment solutions. Schott Pharma produces around 13 billion products per year.
Photo courtesy of Schott/Oana Szekely

Schott has established a standalone company for its pharma business to advance its growth strategy. As a pioneer in pharma drug containment and system solutions, the international technology group’s pharma division has grown faster than the market in recent years. As part of the carve-out, the pharma business will operate under the new name Schott Pharma as of today.

“By creating a separate legal entity for our pharma business, we are generating new opportunities to expedite our profitable growth,” says Schott CEO Dr. Frank Heinricht. “Pharma will remain an integral part of Schott in the future. With this move, we are creating more room for organic and inorganic growth and further potential investments towards becoming climate neutral by 2030.”

Pharma drug containment and system solutions, just as drug manufacturing, are subject to the strictest regulations. Working in a dynamic market with high barriers to entry, Schott Pharma is optimally positioned to develop new opportunities. The portfolio ranges from high-quality vials to glass and polymer syringes to cartridges and ampoules. The company produces approximately 13 billion products yearly to serve modern drug categories, such as mRNA-based drugs and biopharmaceuticals.

“In recent years, our sales in the pharma division have increased continuously, with the latest figure growing double-digit to EUR 650 million for the 2021 fiscal year—although the share of sales related to COVID-19 was only about 3%,” says CFO Dr. Jens Schulte. The company is investing a three-digit million Euro figure to meet worldwide demand.

Currently, the Schott Group’s pharma division is operating as a standalone company. However, the carve-out is expected be completed by the end of this year.     


Fill out the form below to request more information about Schott Establishes Standalone Company for Pharma Business
Where the Entire Industry Meets
Discover solutions from 2,000+ exhibitors to advance your operations and network with colleagues at PACK EXPO International, Oct 23-26.
REGISTER TODAY
Where the Entire Industry Meets
Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Take Quiz
Test Your Supply Chain Smarts